Table 3.
Distribution of pre-transplant factors associated with TCR γδ cell concentrations 56 days after transplantation (χ2).
| Total | Day 56 TCR γδ high (>21 × 106/L) | Day 56 TCR γδ low (<21 × 106/L) | P-value | |
|---|---|---|---|---|
| N | 104 | 52 | 52 | |
| Age | ||||
| ≤45 | 23 | 13 (57%) | 10 (43%) | 0.48 |
| >45 | 81 | 39 (48%) | 42 (52%) | |
| Disease type | ||||
| AML/MDS | 68 | 39 (57%) | 29 (43%) | 0.04 |
| Other | 36 | 13 (36%) | 23 (64%) | |
| Donor age | ||||
| <30 | 59 | 35 (59%) | 24 (41%) | 0.03 |
| >30 | 45 | 17 (38) | 28 (62%) | |
| Disease stage | ||||
| Early | 59 | 28 (47%) | 31 (53%) | 0.55 |
| Intermediate/Late | 45 | 24 (53%) | 21 (47%) | |
| Recipient CMV serological status | ||||
| Positive | 71 | 35 (49%) | 36 (51%) | 0.83 |
| Negative | 33 | 17 (52%) | 16 (48%) | |
| Donor CMV serological status | ||||
| Positive | 46 | 18 (39%) | 28 (61%) | 0.08 |
| Negative | 58 | 34 (59%) | 24 (41%) | |
| Donor-recipient sex | ||||
| Female-male | 10 | 4 (40%) | 6 (60%) | 0.51 |
| Other | 94 | 48 (51%) | 46 (49%) | |
| Donor type | ||||
| MRD | 21 | 11 (52%) | 10 (48%) | 0.36 |
| MUD | 81 | 41 (51%) | 40 (49%) | |
| Haplo-identical | 2 | 0 (0%) | 2 | |
| HLA-match | ||||
| 9/10 or 10/10 allele match | 93 | 50 (54%) | 43 (46%) | 0.03 |
| Other (antigen MM+haplo-identical) | 11 | 2 (18%) | 9 (82%) | |
| Stem cell source | ||||
| BM | 15 | 3 (20%) | 12 (80%) | 0.01 |
| PBSC | 89 | 49 (55%) | 40 (45%) | |
| Conditioning regimen | ||||
| Myeloablative | 48 | 26 (54%) | 22 (46%) | 0.43 |
| Non-myeloablative | 56 | 26 (46%) | 30 (54%) | |
| ATG | ||||
| Yes | 11 | 6 (55%) | 5 (45%) | 0.75 |
| No | 93 | 46 (49%) | 47 (51%) |
MDR, matched related donor; MUD, matched unrelated donor; MM, mismatch; BM, bone marrow; PBSC, peripheral blood stem cells; ATG, anti-thymocyte-globulin. The italic values represent p-values equal to or below 0.05.